Prostate cancer and prostatic diseases

Keyphrases

Publications

2024

Timothy John Daskivich, Aurash Naser-Tavakolian, Rebecca Gale, Michael Luu, Nadine A Friedrich, Abhi Venkataramana, Dmitry Khodyakov, Edwin Posadas, Howard M Sandler, Brennan Spiegel, Stephen J Freedland
Variation in communication of side effects in prostate cancer treatment consultations. Prostate cancer and prostatic diseases (2024)
Valentina Russo, Lara Tamburrino, Simone Morselli, Cristina Sani, Elisabetta Baldi, Arcangelo Sebastianelli, Maria Rosaria Raspollini, Alessandra Mongia, Valentina Carradori, Eleonora Lallo, Armelle Munnia, Simonetta Bisanzi, Sara Marchiani, Carmen Beatriz Visioli, Stefano Rapi, Sergio Serni, Marco Zappa, Francesca Carozzi, Marco Peluso
Hyperglycemia and microRNAs in prostate cancer. Prostate cancer and prostatic diseases (2024)
Ryan E Fecteau, Bridget F Koontz, Karen E Hoffman, Susan Halabi, Lauren E Howard, Monika Anand, Daniel J George, Tian Zhang, William R Berry, W Robert Lee, Michael R Harrison, Paul G Corn, Andrew J Armstrong
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer. Prostate cancer and prostatic diseases (2024)
Zeynep B Zengin, Nicholas C Henderson, Joseph J Park, Alicia Ali, Charles Nguyen, Clara Hwang, Pedro C Barata, Mehmet A Bilen, Laura S Graham, George Mo, Deepak Kilari, Abhishek Tripathi, Matthew Kyle Labriola, Shoshana Rothstein, Rohan Garje, Vadim S Koshkin, Vaibhav G Patel, Michael Thomas Schweizer, Andrew J Armstrong, Rana R McKay, Ajjai Alva, Tanya Barauskas Dorff
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate cancer and prostatic diseases (2024)
Neal D Shore, Emmanuel S Antonarakis, Ashley Ross, Catherine Marshall, Kelly Stratton, Adanma Ayanambakkam, Michael Cookson, Rana R McKay, Alan H Bryce, Marina Kaymakcalan
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases (2024)
Zeynep B Zengin, Nicholas C Henderson, Joseph J Park, Alicia Ali, Charles Nguyen, Clara Hwang, Pedro C Barata, Mehmet A Bilen, Laura S Graham, George Mo, Deepak Kilari, Abhishek Tripathi, Matthew Kyle Labriola, Shoshana Rothstein, Rohan Garje, Vadim S Koshkin, Vaibhav G Patel, Michael Thomas Schweizer, Andrew J Armstrong, Rana R McKay, Ajjai Alva, Tanya Barauskas Dorff
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate cancer and prostatic diseases (2024)
Riccardo Bertolo, Alessandro Veccia, Alessandro Antonelli
Democratizing robotic prostatectomy: navigating from novel platforms, telesurgery, and telementoring. Prostate cancer and prostatic diseases (2024)
Vincenza Conteduca, Piergiorgio Di Tullio, Rossana Allamprese, Giuseppina Bruno, Cristian Lolli, Giuseppe Schepisi, Aldo Rosano, Guido Giordano, Marianna Garofoli, Vincenzo Emanuele Chiuri, Lucia Fratino, Elisa Zanardi, Luca Galli, Francesco Massari, Ugo Giovanni Falagario, Pasquale Rescigno, Giuseppe Fornarini, Francesca Sanguedolce, Daniele Santini, Giuseppe Procopio, Orazio Caffo, Giuseppe Carrieri, Matteo Landriscina, Ugo De Giorgi
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care. Prostate cancer and prostatic diseases (2024)
Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada, Ali T Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia, Vivek Narayan, Mark N Stein, Kevin K Zarrabi, Akash Patniak, Mehmet A Bilen, Milan Radovich, George Sledge, Wafik S El-Deiry, Elisabeth I Heath, Dave S B Hoon, Chadi Nabhan, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate cancer and prostatic diseases (2024)
Masaki Shiota, Tokiyoshi Tanegashima, Shuichi Tatarano, Toshiyuki Kamoto, Hideyasu Matsuyama, Hideki Sakai, Tsukasa Igawa, Tomomi Kamba, Naohiro Fujimoto, Akira Yokomizo, Seiji Naito, Masatoshi Eto
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study. Prostate cancer and prostatic diseases (2024)
Qiyu Zhu, Xingyu Xiong, Qian Zheng, Qi Deng, Yun Hao, Dingbang Liu, Jiaming Zheng, Guangyue Zhang, Jiakun Li, Lu Yang
High-intensity interval training versus moderate-intensity continuous training for localized prostate cancer under active surveillance: a systematic review and network meta-analysis. Prostate cancer and prostatic diseases (2024)
Hao Zeng, Sha Zhu, Jing Li, Ni Chen, Yao Zhu
MDT perspective: intraductal carcinoma of the prostate: implication for diagnosis and treatment. Prostate cancer and prostatic diseases (2024)
Zeynep B Zengin, Nicholas C Henderson, Joseph J Park, Alicia Ali, Charles Nguyen, Clara Hwang, Pedro C Barata, Mehmet A Bilen, Laura S Graham, George Mo, Deepak Kilari, Abhishek Tripathi, Matthew Kyle Labriola, Shoshana Rothstein, Rohan Garje, Vadim S Koshkin, Vaibhav G Patel, Michael Thomas Schweizer, Andrew J Armstrong, Rana R McKay, Ajjai Alva, Tanya Barauskas Dorff
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate cancer and prostatic diseases (2024)
Andrew B Nixon, Yingmiao Liu, Qian Yang, Bin Luo, Mark D Starr, John C Brady, Wm Kevin Kelly, Himisha Beltran, Michael J Morris, Daniel J George, Andrew J Armstrong, Susan Halabi
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab. Prostate cancer and prostatic diseases (2024)

volume 27, number 2, 2024

Hao Zeng, Sha Zhu, Jing Li, Ni Chen, Yao Zhu
MDT perspective: intraductal carcinoma of the prostate: implication for diagnosis and treatment. Prostate cancer and prostatic diseases 27 (2) (2024)
Mohammed Hegazy, Khaled Z Sheir, Mohamed A Gaballah, Ahmed M Elshal
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction. Prostate cancer and prostatic diseases 27 (2) (2024)
Guilherme Lemos, Cícera Madri Alves de Souza Fernandes, Fábio Henrique Silva, Fabiano Beraldi Calmasini
The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy. Prostate cancer and prostatic diseases 27 (2) (2024)
Mohammed Hegazy, Khaled Z Sheir, Mohamed A Gaballah, Ahmed M Elshal
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction. Prostate cancer and prostatic diseases 27 (2) (2024)
Mohammed Hegazy, Khaled Z Sheir, Mohamed A Gaballah, Ahmed M Elshal
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction. Prostate cancer and prostatic diseases 27 (2) (2024)
Tommaso Cai, Irene Tamanini, Katia Odorizzi, Luca Gallelli, Massimiliano Lanzafame, Sandra Mazzoli, Paolo Lanzafame, Orietta Massidda, Alessandro Palmieri, Florian M E Wagenlehner, Truls E Bjerklund Johansen, Cosimo De Nunzio
The diagnostic yield of the Meares & Stamey test can be significantly improved by symptom-based patient selection and the experience of the test performer. Prostate cancer and prostatic diseases 27 (2) (2024)
F Dibitetto, C Fede Spicchiale, R Castellucci, S Sansalone, A Akhundov, L Defidio, M De Dominicis
Extraperitoneal robot assisted laparoscopic prostatectomy with Versius system: single centre experience. Prostate cancer and prostatic diseases 27 (2) (2024)
Guilherme Lemos, Cícera Madri Alves de Souza Fernandes, Fábio Henrique Silva, Fabiano Beraldi Calmasini
The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy. Prostate cancer and prostatic diseases 27 (2) (2024)
Mohammed Hegazy, Khaled Z Sheir, Mohamed A Gaballah, Ahmed M Elshal
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction. Prostate cancer and prostatic diseases 27 (2) (2024)
Hao Zeng, Sha Zhu, Jing Li, Ni Chen, Yao Zhu
MDT perspective: intraductal carcinoma of the prostate: implication for diagnosis and treatment. Prostate cancer and prostatic diseases 27 (2) (2024)
Cosimo De Nunzio, Riccardo Lombardo
Best of 2023 in Prostate Cancer and Prostatic Diseases. Prostate cancer and prostatic diseases 27 (2) (2024)

volume 27, number 3, 2024

Steven A Kaplan, Jared L Moss, Sheldon J Freedman
Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study). Prostate cancer and prostatic diseases 27 (3) (2024)
Luca Gemma, Alessio Pecoraro, Arcangelo Sebastianelli, Pietro Spatafora, Francesco Sessa, Rossella Nicoletti, Stavros Gravas, Riccardo Campi, Sergio Serni, Mauro Gacci
Impact of minimally invasive surgical procedures for Male Lower Urinary Tract Symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review. Prostate cancer and prostatic diseases 27 (3) (2024)
Roberto Miano, Guglielmo Manenti, Luca Orecchia
TRexit is going one step further. Prostate cancer and prostatic diseases 27 (3) (2024)
Primo N Lara, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta van Loan, Maha H A Hussain, Shilpa Gupta, Jingsong Zhang, Mamta Parikh, Przemyslaw Twardowski, David I Quinn, Michael LeBlanc, Ian Thompson, Archana M Agarwal
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate cancer and prostatic diseases 27 (3) (2024)
Chloe Shu Hui Ong, Yu Xi Terence Law, Lin Kyaw, Qi Yang Lim, Tim Loke, Qing Hui Wu, Ho Yee Tiong, Edmund Chiong
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis. Prostate cancer and prostatic diseases 27 (3) (2024)
Mohamed Shelan, Vérane Achard, Felix Appiagyei, Lucas Mose, Thomas Zilli, Christian D Fankhauser, Constantinos Zamboglou, Osama Mohamad, Daniel Matthias Aebersold, Richard Cathomas
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. Prostate cancer and prostatic diseases 27 (3) (2024)
Steven A Kaplan, Jared L Moss, Sheldon J Freedman
Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study). Prostate cancer and prostatic diseases 27 (3) (2024)
Hazem Elmansy
Editorial comment on "Reevaluating 'Top-Down' HoLEP: the case for anterior fibromuscular stroma as a surgical landmark". Prostate cancer and prostatic diseases 27 (3) (2024)
Riccardo Lombardo, Giorgio Ivan Russo, Matteo Romagnoli, Giorgia Tema, Antonio Nacchia, Antonio Franco, Antonio Cicione, Giorgio Franco, Andrea Tubaro, Cosimo De Nunzio
Yoga, benign prostatic hyperplasia and lower urinary tract symptoms: a new path for clinical trials. Prostate cancer and prostatic diseases 27 (3) (2024)
Alberto Martini, Lieke Wever, Timo F W Soeterik, Arnas Rakauskas, Christian Daniel Fankhauser, Josias Bastian Grogg, Enrico Checcucci, Daniele Amparore, Luciano Haiquel, Lara Rodriguez-Sanchez, Guillaume Ploussard, Peng Qiang, Andres Affentranger, Alessandro Marquis, Giancarlo Marra, Otto Ettala, Fabio Zattoni, Ugo Giovanni Falagario, Mario De Angelis, Claudia Kesch, Maria Apfelbeck, Tarek Al-Hammouri, Alexander Kretschmer, Veeru Kasivisvanathan, Felix Preisser, Emilie Lefebvre, Jonathan Olivier, Jan Philipp Radtke, Giuseppe Carrieri, Fabrizio Dal Moro, Peter Boström, Ivan Jambor, Paolo Gontero, Peter K Chiu, Hubert John, Petr Macek, Francesco Porpiglia, Thomas Hermanns, Roderick C N van den Bergh, Jean-Paul A van Basten, Giorgio Gandaglia, Massimo Valerio, null null
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy. Prostate cancer and prostatic diseases 27 (3) (2024)
Primo N Lara, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta van Loan, Maha H A Hussain, Shilpa Gupta, Jingsong Zhang, Mamta Parikh, Przemyslaw Twardowski, David I Quinn, Michael LeBlanc, Ian Thompson, Archana M Agarwal
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate cancer and prostatic diseases 27 (3) (2024)
Alberto Martini, Lieke Wever, Timo F W Soeterik, Arnas Rakauskas, Christian Daniel Fankhauser, Josias Bastian Grogg, Enrico Checcucci, Daniele Amparore, Luciano Haiquel, Lara Rodriguez-Sanchez, Guillaume Ploussard, Peng Qiang, Andres Affentranger, Alessandro Marquis, Giancarlo Marra, Otto Ettala, Fabio Zattoni, Ugo Giovanni Falagario, Mario De Angelis, Claudia Kesch, Maria Apfelbeck, Tarek Al-Hammouri, Alexander Kretschmer, Veeru Kasivisvanathan, Felix Preisser, Emilie Lefebvre, Jonathan Olivier, Jan Philipp Radtke, Giuseppe Carrieri, Fabrizio Dal Moro, Peter Boström, Ivan Jambor, Paolo Gontero, Peter K Chiu, Hubert John, Petr Macek, Francesco Porpiglia, Thomas Hermanns, Roderick C N van den Bergh, Jean-Paul A van Basten, Giorgio Gandaglia, Massimo Valerio, null null
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy. Prostate cancer and prostatic diseases 27 (3) (2024)
Romain Diamand, Alexandre Peltier, Simone Albisinni
Transrectal prostate biopsy: easy, effective and safe. Prostate cancer and prostatic diseases 27 (3) (2024)
Steven A Kaplan, Jared L Moss, Sheldon J Freedman
Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study). Prostate cancer and prostatic diseases 27 (3) (2024)
Kai Zhang, Phillip D Stricker, Martin Löhr, Michael Stehling, Michel Suberville, Olivier Cussenot, Luca Lunelli, Chi-Fai Ng, Jeremy Yuen Chun Teoh, Pilar Laguna, Jean J M C H de la Rosette
A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate cancer and prostatic diseases 27 (3) (2024)
Cody M Anger, James L Stallworth, Soroush Rais-Bahrami
Integrating risk calculators into routine clinical workflow for the detection of prostate cancer: next steps to achieve widespread adoption. Prostate cancer and prostatic diseases 27 (3) (2024)
Frederique B Denijs, Meike J van Harten, Jonas J L Meenderink, Renée C A Leenen, Sebastiaan Remmers, Lionne D F Venderbos, Roderick C N van den Bergh, Katharina Beyer, Monique J Roobol
Risk calculators for the detection of prostate cancer: a systematic review. Prostate cancer and prostatic diseases 27 (3) (2024)
Mohamed Shelan, Vérane Achard, Felix Appiagyei, Lucas Mose, Thomas Zilli, Christian D Fankhauser, Constantinos Zamboglou, Osama Mohamad, Daniel Matthias Aebersold, Richard Cathomas
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. Prostate cancer and prostatic diseases 27 (3) (2024)
Mohamed Shelan, Vérane Achard, Felix Appiagyei, Lucas Mose, Thomas Zilli, Christian D Fankhauser, Constantinos Zamboglou, Osama Mohamad, Daniel Matthias Aebersold, Richard Cathomas
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. Prostate cancer and prostatic diseases 27 (3) (2024)
David Eugenio Hinojosa-Gonzalez, Affan Zafar, Gal Saffati, Shane M Kronstedt, Dimitar V Zlatev, Mohit Khera
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis. Prostate cancer and prostatic diseases 27 (3) (2024)
Kai Zhang, Phillip D Stricker, Martin Löhr, Michael Stehling, Michel Suberville, Olivier Cussenot, Luca Lunelli, Chi-Fai Ng, Jeremy Yuen Chun Teoh, Pilar Laguna, Jean J M C H de la Rosette
A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate cancer and prostatic diseases 27 (3) (2024)
Leslie Claire Licari, Eugenio Bologna, Celeste Manfredi, Antonio Franco, Francesco Ditonno, Cosimo De Nunzio, Alessandro Antonelli, Giuseppe Simone, Marco De Sio, Luca Cindolo, Ephrem O Olweny, Edward E Cherullo, Costantino Leonardo, Riccardo Autorino
Incidence and management of BPH surgery-related urethral stricture: results from a large U.S. database. Prostate cancer and prostatic diseases 27 (3) (2024)
Jehonathan H Pinthus, Wilhelmina C M Duivenvoorden
Cardiovascular risk in ADT recipients: does the type of ADT matter? Prostate cancer and prostatic diseases 27 (3) (2024)
Kai Zhang, Phillip D Stricker, Martin Löhr, Michael Stehling, Michel Suberville, Olivier Cussenot, Luca Lunelli, Chi-Fai Ng, Jeremy Yuen Chun Teoh, Pilar Laguna, Jean J M C H de la Rosette
A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate cancer and prostatic diseases 27 (3) (2024)
Yu-Hsiang Lin, Horng-Heng Juang
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.'s findings. Prostate cancer and prostatic diseases 27 (3) (2024)